Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T

Also Uses Immune Cloaking

Executive Summary

Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.

You may also be interested in...



CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits

Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.

Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.

Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science

Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."

Topics

Related Companies

UsernamePublicRestriction

Register

SC145708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel